HotAvitag
Biotinylated Human IL-15 R alpha / CD215 Protein, Fc,Avitag™ (MALS verified)Cat. No. ILA-H82F4
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| IL-15 R alpha | HOTAvitag ILA-H82F4 | Biotinylated Human IL-15 R alpha / CD215 Protein, Fc,Avitag™ (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug | |
| IL-15 R alpha | HOT ILA-HP2F6 | PE-Labeled Human IL-15 R alpha / CD215 Protein, Fc Tag (Site-specific conjugation) | Human | HEK293 | ![]() | $450.00 25tests | ||
| IL-15 R alpha | HOT ILA-H5253 | Human IL-15 R alpha / CD215 Protein, Fc Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $340.00 100ug | |
| IL-15 R alpha | HOT ILA-HF255 | FITC-Labeled Human IL-15 R alpha / CD215 Protein, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $330.00 25ug | |
| IL-15 R alpha | Avitag ILA-H82E5 | Biotinylated Human IL-15 R alpha Protein, His,Avitag™ (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug | |
| IL-15 R alpha | Mouse IL-15 R alpha / CD215 Protein, Fc Tag | Mouse | HEK293 | ![]() | SDS-PAGE | $360.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| SHR-1501 | SHR-1501 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Neoplasms; Urinary Bladder Neoplasms | Details |
| Avipendekin pegol | NKTR-255 | Phase 2 Clinical | Nektar Therapeutics | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck | Details |
| ASKG-915 | ASKG-915 | Phase 2 Clinical | Askgene Pharma | Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| VG-201 | VG-201 | Phase 2 Clinical | ViroGin Biotech Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| FL115 | FL-115; FL115 | Phase 2 Clinical | Suzhou Forlongbiotech Co Ltd | Solid tumours; Urinary Bladder Neoplasms | Details |
| Efbalropendekin alfa | XmAb-24306; RG-6323; RO-7310729; XmAb-306 | Phase 1 Clinical | Xencor Inc | Multiple Myeloma; Solid tumours | Details |
| BJ-001(Boji Biomedical Technology) | BJ-001 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Communicable Diseases; Neoplasm Metastasis; Solid tumours | Details |
| ASKG-315 | ASKG-315; ASKG-215b; ASKG-215β | Phase 1 Clinical | Askgene Pharma | Neoplasms; Solid tumours | Details |
| VG-203 | VG-203; VG2062; VG-2062 | Phase 1 Clinical | Fenojian Biotechnology (Nantong) Co Ltd, Shanghai Funuojian Biotechnology Co Ltd, Virogin Biotech (Shenzhen) Ltd, ViroGin Biotech Ltd | Breast Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Solid tumours | Details |
| BAT-7205 | BAT7205; BAT-7205 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Neoplasm Metastasis; Solid tumours | Details |
| RC-198 | RC-198 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details | |
| QL-415 | QL-415 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
| Recombinant human interleukin 15(Beijing Kawin) | Phase 1 Clinical | Beijing Kawin Technology Share-Holding Co Ltd | Solid tumours | Details |